1418274-56-2

Upstream product

• 13631-21-5 4-bromo-3-chlorophenol 
• 946426-89-7 4-(hydroxymethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole 
• 1268245-50-6 4-(chloromethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole 
• 1418274-69-7 ethyl 5-((1s,3s)-3-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)-3-hydroxycyclobutyl)-1-isopropyl-1H-pyrazole-3-carboxylate 
• 1418274-31-3 4-((4-Bromo-3-chlorophenoxy)methyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-isoxazole 
• 1418274-43-7 Ethyl 1-isopropyl-5-(3-oxocyclobutyl)-1H-pyrazole-3-carboxylate 
• 1418274-42-6 Ethyl 1-isopropyl-5-(3-methylenecyclobutyl)-1H-pyrazole-3-carboxylate 
• 1418274-41-5 Ethyl 4-(3-methylenecyclobutyl)-2,4-dioxobutanoate 
• 25303-66-6 1-(3-methylenecyclobutyl)ethanone 
• 15760-35-7 3-methylenecyclobutanecarbonitrile 

Relevant academic research and scientific papers

NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS

The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.